{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AGIO",
  "name": "Agios Pharmaceuticals, Inc.",
  "url": "https://orbyd.app/dossiers/AGIO/",
  "json_url": "https://orbyd.app/dossiers/AGIO.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Mitapivat SCD label-expansion re-rate: positive RISE UP Phase 3 (2026-06-15) plus FDA Priority Review (2026-07-07) set a 2026-11-01 PDUFA binary. The acceptance pop is digested and backup asset tebapivat's 2026-07-21 Phase 2 failure thins the pipeline, so the tape drifts into a decision still three-plus months out.",
  "invalidation_trigger": "A weekly close below $29 fills the 2026-07-07 Priority-Review gap and negates the SCD re-rate breakout; a complete response letter or restrictive label at the ~2026-11-01 mitapivat PDUFA breaks the thesis outright.",
  "catalyst_date": "2026-11-01",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Cleaner fresh entry is a pullback into the high-$20s gap shelf rather than chasing the post-acceptance extension.",
    "PDUFA goal date 2026-11-01 for mitapivat sNDA in sickle cell disease — the defining binary; size and stops around late-October event risk.",
    "Tebapivat (Agios's backup oral PK activator) reported NEUTRAL Phase 2 SCD topline on 2026-07-21 and development was stopped — removes a pipeline hedge but does NOT touch mitapivat's positive RISE UP Phase 3 package; don't conflate the two drugs.",
    "Q2 2026 earnings estimated ~early August (unconfirmed) — watch Pyrukynd run-rate, SCD launch-prep spend, and cash runway.",
    "Comp risk: GBT's Oxbryta was withdrawn over safety — an SCD label/ADCOM safety signal on mitapivat is the key downside trigger.",
    "PT landscape: HC Wainwright Buy $52 (lowered 2026-07-21); 2026-07-07 cluster — Truist $41 Buy, B of A $46 Buy, RBC $32 Sector Perform, JPM Neutral $31 (cut 2026-06-11, pre-acceptance).",
    "Cleaner fresh entry is a pullback into the high-$20s gap shelf rather than chasing the post-acceptance extension into a months-away binary.",
    "Whale/options-flow alert on AGIO 2026-07-21 — monitor for directional positioning into the Q2 print."
  ],
  "body_markdown": "## Current Thesis\nThe leg on offer is a label-expansion re-rate: mitapivat (Pyrukynd), already commercial in the niche pyruvate-kinase-deficiency and thalassemia settings, moving into sickle cell disease — a ~100,000-patient US market an order of magnitude larger than the current base. Positive RISE UP Phase 3 data (EHA 2026, 2026-06-15) de-risked efficacy, and the FDA accepted the sNDA with Priority Review on 2026-07-07, setting a 2026-11-01 PDUFA goal date and driving a ~15% single-session gap. That approval decision is the payoff event. The acceptance pop is already digested, and the 2026-07-21 discontinuation of backup asset tebapivat after neutral Phase 2 SCD data thins the pipeline behind mitapivat without touching its own positive Phase 3 package. With the hard catalyst three-plus months out, the intervening tape is consolidation.\n\n## Bull Case\n- RISE UP Phase 3 (presented EHA 2026, 2026-06-15): mitapivat showed a 40.6% hemoglobin response rate and a 41.1% reduction in transfusion burden versus placebo in SCD — a clean primary readout that hardens the regulatory filing.\n- FDA accepted the mitapivat sNDA with Priority Review (2026-07-07), PDUFA goal date 2026-11-01; Priority Review flags a potential meaningful improvement over available therapy, and the shares gapped ~15% that session.\n- HC Wainwright maintained Buy on 2026-07-21 with a $52 target — above the 2026-07-07 raise cluster (Truist $41 Buy, B of A $46 Buy) — so the top of the sell-side range moved higher even after the tebapivat setback.\n- Oral PK-activator mechanism differentiates mitapivat from the withdrawn Oxbryta and from injectable and gene-therapy competitors; the SCD population dwarfs the PK-deficiency base already generating Pyrukynd revenue.\n- Commercial infrastructure is in place — Pyrukynd approved in PK deficiency since 2022 and later thalassemia — lowering launch-execution risk relative to a first-approval biotech.\n\n## Bear Case\n- The binary sits at 2026-11-01, more than three months out; the Priority-Review pop already fired, so a buyer at current levels funds a long drift into an unresolved decision carrying complete-response-letter and narrow-label risk.\n- Tebapivat, Agios's second oral PK activator, posted neutral Phase 2 SCD topline on 2026-07-21 and was discontinued — evidence that the mechanism does not automatically translate in sickle cell, and a subtraction from pipeline optionality.\n- SCD is a regulatory minefield: GBT's Oxbryta was pulled over safety, and reviewers weigh hemoglobin surrogate endpoints against hard outcomes such as vaso-occlusive-crisis reduction and transfusion independence.\n- The company still burns cash at the commercial stage; SCD launch spend front-loads ahead of any approval-driven revenue by several quarters.\n- The 2026-07-07 target spread ran from RBC's $32 Sector Perform and JPM's $31 Neutral (cut 2026-06-11, pre-acceptance) up to B of A's $46, so at least two desks see limited-to-no upside from the post-pop print.\n\n## Setup & Price Structure\nThe 2026-07-07 acceptance produced a ~15% gap-up on elevated volume, breaking out of the base built after JPM's 2026-06-11 target cut to $31. The shares settled in the low-to-mid $30s, bracketed by an analyst spread from the $31–$32 RBC/JPM cluster to HC Wainwright's $52. The tebapivat discontinuation on 2026-07-21 delivered the first real negative print since the run and is the near-term test of whether the gap holds. The breakout has not retested; a pullback into the high-$20s pre-spike shelf would offer a lower-risk entry than chasing an extension that has no fresh catalyst until the Q2 print. Whale and options-flow alerts flagged AGIO on 2026-07-21, worth monitoring for directional positioning into earnings. With the defining event three-plus months away, range-bound consolidation is the base case between now and the fall.\n\n## Catalyst Calendar (next 30 days)\n\n- Q2 2026 earnings — estimated ~early August 2026 (unconfirmed date); watch Pyrukynd run-rate, SCD launch-prep opex, and cash-runway commentary.\n- No hard binary inside the 30-day window; the defining mitapivat PDUFA decision is dated 2026-11-01, outside this window.\n\n## Elapsed catalysts\n\n- Continued SCD sell-side revisions — HC Wainwright already reset to $52 Buy on 2026-07-21; further target moves in either direction would confirm or fade the re-rate. *(passed 19d ago)*\n\n## What Would Change Our Mind\nA weekly close below $29 fills the 2026-07-07 Priority-Review gap and negates the breakout, marking the re-rate as failed before the decision arrives. Holding the low-$30s shelf into a confirmed Q2 print with disciplined launch spend would keep the base intact for a run into the November event. The thesis breaks outright on a complete response letter or a restrictive/black-box label at the ~2026-11-01 PDUFA, or on a mitapivat SCD safety signal echoing the Oxbryta withdrawal. A read-through from additional PK-activator setbacks would compound the tebapivat concern.\n\n## Correlation Notes\nAGIO trades as a single-asset regulatory binary rather than a beta name; the dominant driver is idiosyncratic FDA risk into 2026-11-01, not the XBI tape. Read-across runs to the SCD treatment complex — Oxbryta's withdrawal set the safety bar, and competing SCD gene therapies (Vertex/CRISPR's Casgevy, bluebird's Lyfgenia) frame the payer and durability debate mitapivat's oral profile argues against. The tebapivat failure is a within-franchise correlation: it prices the PK-activator mechanism's SCD hit rate, so sentiment spillover to mitapivat is the risk to watch even though the Phase 3 asset stands on its own data. Broad biotech factors — rate moves, XBI fund flows — stay secondary until the decision nears.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T11:25:33+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}